Emilio F. Giunta
Meldola, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Journal: The New England journal of medicine
Published: October 22, 2025
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.
Journal: Prostate cancer and prostatic diseases
Published: October 16, 2025
Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?
Journal: The Journal of pathology
Published: September 03, 2025
Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future prospectives.
Journal: Discover oncology
Published: August 11, 2025
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.
Journal: European journal of nuclear medicine and molecular imaging
Published: July 14, 2025
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 09, 2025
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Journal: Expert review of anticancer therapy
Published: December 24, 2024
Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients.
Journal: The oncologist
Published: December 07, 2024
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 26, 2024
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy?
Journal: Cancers
Published: May 30, 2024
New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact.
Journal: Expert opinion on drug metabolism & toxicology
Published: May 23, 2024
Last Updated: 09/26/2026